title: Mutant, wild type, or overall p53 expression: freedom from clinical progression in tumours of astrocytic lineage.
abstract: Abnormalities of the p53 tumor-suppressor gene are found in a significant proportion of astrocytic brain tumours. We studied tumour specimens from 74 patients evaluated over 20 years at the Massachusetts General Hospital, where clinical outcome could be determined and sufficient pathologic material was available for immunostaining. p53 expression studies employed an affinity-purified p53 monoclonal antibody, whose specificity was verified in absorption studies and, in a minority of cases, a second antibody recognising a different epitope of p53. Significant overexpression of p53 protein was found in 48% of the 74 tumours included in this series and high levels of expression were associated with higher mortality from astrocytic tumours (P<0.001, log rank). Multivariate analyses revealed that immunohistochemically detected p53 was an independent marker of shortened progression-free and overall actuarial survival in patients with astrocytic tumours, suggesting that increased expression of p53 plays an important role in the pathobiology of these tumours. In a subset of 36 cases, coding regions of the p53 gene were completely sequenced via SSCP and direct DNA sequencing, revealing that overexpression of p53 protein is not always associated with point mutations in conserved exons of the p53 gene. Finally, we confirmed p53 protein expression in early-passage human glioma cell lines of known p53 mutational status and immunostaining scores. Although grade continues to be the strongest prognostic variable, the use of p53 staining as a prognostic indicator, in contrast to mutational DNA analyses, may be a useful adjunct in identifying patients at higher risk of treatment failure.
authors.affiliation: Division of Radiation Oncology, Radiation and Cellular Biology Laboratory, Department of Radiology, University of California, San Diego, CA, USA. fpardo@ucsd.edu
authors.forename: F S
authors.initials: FS
authors.lastname: Pardo
authors.forename: D W
authors.initials: DW
authors.lastname: Hsu
authors.forename: R
authors.initials: R
authors.lastname: Zeheb
authors.forename: J T
authors.initials: JT
authors.lastname: Efird
authors.forename: P G
authors.initials: PG
authors.lastname: Okunieff
authors.forename: D M
authors.initials: DM
authors.lastname: Malkin
mesh_terms: D001254:Astrocytoma / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D019070:Cell Lineage; D004252:DNA Mutational Analysis; D004273:DNA, Neoplasm / Q000235:genetics; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D008404:Massachusetts; D008875:Middle Aged; D017354:Point Mutation / Q000235:genetics*; D016133:Polymerase Chain Reaction; D018807:Polymorphism, Single-Stranded Conformational; D011379:Prognosis; D012307:Risk Factors; D016159:Tumor Suppressor Protein p53 / Q000235:genetics* / Q000378:metabolism*
chemical_list: D004273:DNA, Neoplasm; D016159:Tumor Suppressor Protein p53